Article

Oculus device receives FDA premarket approval

The FDA has granted premarket approval to a new pachymeter/auto-refractor/keratometer (PARK 1, Oculus).

Key Points

Lynwood, WA-The FDA has granted premarket approval to a new pachymeter/auto-refractor/keratometer (PARK 1, Oculus).

The device was launched at the annual meeting of the American Academy of Ophthalmology in Atlanta.

The instrument is designed to photograph the eye and obtain a Scheimpflug image of the cornea to evaluate its thickness, according to the company. The implanted ophthalmic refractometer measures the refractive power of the eye.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.